Farmakologiya: bemorlar uchun qo‘llanma

Biologik faol qo‘shimchalardan oqilona foydalanish

Mualliflar: National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA)

Shifokorlar bahosi: Shifokorlar hali baho bermagan

Tarjima. Ingliz tilidan tarjima (mashina tarjimasi, shifokor tekshiruvini talab qiladi). AIVITA izohlari kursivda. Tarjimon: AIVITA.

Русская версия

103Shoshilinch holat

Ko‘krakda kuchli og‘riq, nafas qisishi, hushdan ketish, nutq yoki harakat buzilishi kabi xavfli belgilar bo‘lsa — darhol 103 ga qo‘ng‘iroq qiling.

ⓘ Ma’lumot shifokor maslahatini almashtirmaydi. Tashxis va davolashni faqat shifokor belgilaydi.

O'zbek farmatsevti oq xalatda bemorga zamonaviy dorixona stendida joylashgan turli biologik faol qo'shimchalar va o'simlik preparatlarini ko'rsatmoqda

Asosiy xulosalar

Biologik faol qo‘shimchalar haqida qanchalik ko‘p bilamiz?

Biologik faol qo‘shimchalar (BFQ) haqidagi ilmiy dalillar hajmi juda turlicha: ayrimlari haqida ma’lumot ko‘p, boshqalari haqida esa juda kam.

BFQ samaradorligi haqida nimalar ma’lum?

  • Tadqiqotlar ba’zi BFQ biroz foyda keltirishi mumkinligini ko‘rsatgan, masalan, vaqt mintaqalari almashinuvi sindromida (jetlagda) melatonin, boshqalari esa deyarli yoki umuman foyda keltirmasligi mumkin, masalan, demensiyada ginkgo.
  • Do‘konlardan yoki internetdan sotib oladigan qo‘shimchalaringiz tadqiqotlarda sinovdan o‘tkazilgan mahsulotlardan muhim jihatlari bilan farq qilishi mumkin.
  • Tadqiqotlarning aksariyati multivitaminlar qabul qilish umrni uzaytirmasligini, kognitiv funksiyalarning pasayishini sekinlashtirmasligini, saraton, yurak kasalliklari yoki qandli diabet bilan kasallanish ehtimolini kamaytirmasligini ko‘rsatadi.

BFQ xavfsizligi haqida nimalar ma’lum?

  • Multivitamin qabul qilish sog‘liq uchun biror xavf tug‘dirishi ehtimoldan yiroq.
  • BFQ siz qabul qilayotgan dorilar bilan o‘zaro ta’sirlashishi yoki sizda ayrim kasalliklar bo‘lsa yoxud sizni operatsiya kutayotgan bo‘lsa, xavf tug‘dirishi mumkin.
  • Ko‘plab BFQ homilador ayollarda, emizikli onalarda yoki bolalarda sinovdan o‘tkazilmagan.
  • BFQ sifatida sotiladigan ayrim mahsulotlar (asosan ozish, jinsiy faollikni oshirish va bodibilding uchun reklama qilinadiganlar) tarkibida BFQga qo‘shish taqiqlangan retseptli dorilar yoki yorliqda ko‘rsatilmagan boshqa moddalar bo‘lishi mumkin. Bu moddalarning ayrimlari xavfli bo‘lishi mumkin.

Biologik faol qo‘shimchalar nima?

AQSh federal qonuni BFQni (dietary supplements) quyidagi mahsulotlar sifatida belgilaydi:

  • ichish orqali qabul qilinadi (masalan, tabletka, kapsula, kukun yoki suyuqlik shaklida);
  • ratsionni to‘ldirish uchun mo‘ljallangan;
  • tarkibida bir yoki bir nechta ozuqaviy modda, jumladan, vitaminlar, minerallar, o‘tlar yoki boshqa o‘simlik komponentlari, aminokislotalar, fermentlar, a’zo yoki bez to‘qimalari yoxud ularning ekstraktlari bor;
  • yorlig‘ida BFQ ekani ko‘rsatilgan.

O‘simlik asosidagi qo‘shimchalar nima?

O‘simlik asosidagi qo‘shimchalar – tarkibida bir yoki bir nechta o‘t bo‘lgan BFQ turi. Ular:

  • ba’zan fitopreparatlar (botanicals) deb ataladi;
  • o‘simliklar, suvo‘tlar, zamburug‘lar yoki ularning birikmasidan tayyorlanadi;
  • choy, ekstrakt, tabletka, kapsula, kukun yoki boshqa shakllarda sotiladi.

AQShda BFQdan foydalanish

2012-yilgi Milliy sog‘liq bo‘yicha so‘rov (National Health Interview Survey) ma’lumotlariga ko‘ra – unda amerikaliklarning tabiiy mahsulotlardan (vitamin va minerallardan tashqari BFQdan) foydalanishi haqida savollar bor edi – 2012-yilda bunday mahsulotlardan kattalarning qariyb 18 foizi va bolalarning taxminan 5 foizi foydalangan.

Milliy sog‘liq va ovqatlanishni tekshirish tadqiqoti (National Health and Nutrition Examination Survey) doirasida 2011–2012-yillarda barcha turdagi BFQdan foydalanish bo‘yicha ma’lumotlar to‘plangan. Unga ko‘ra, amerikalik kattalarning 52 foizi kamida bitta BFQ qabul qilgan. Multivitaminli yoki multivitamin-mineralli qo‘shimchalar (tarkibida 10 yoki undan ortiq vitamin yoki mineral bo‘lgan mahsulot) eng keng tarqalganlaridan biri bo‘lib, ularni barcha kattalarning 31 foizi qabul qilgan. Bu 1999–2000-yillarga nisbatan kamaygan: o‘shanda amerikalik kattalarning 37 foizi multivitaminli yoki multivitamin-mineralli qo‘shimchalar qabul qilishini aytgan. Ayollar BFQni erkaklarga qaraganda ko‘proq qabul qilgan.

Odamlar BFQni nima uchun qabul qiladi?

1-rasm. Amerikalik kattalar biologik faol qo'shimchalar qabul qilishining sabablari (Milliy sog'liq bo'yicha so'rov, 2012-yil)

1-rasm. Amerikalik kattalar biologik faol qo'shimchalar qabul qilishining sabablari (Milliy sog'liq bo'yicha so'rov, 2012-yil) AIVITA sxemasi.

Amerikalik kattalar BFQni ko‘pincha o‘zini yaxshi his qilish uchun qabul qiladi. 2012-yilgi Milliy sog‘liq bo‘yicha so‘rovga ko‘ra, vitamin va minerallardan tashqari BFQ qabul qilgan amerikalik kattalarning 89 foizi ulardan foydalanish sabablarini yaxshi his qilish bilan bog‘lagan, jumladan:

  • umumiy yaxshi his qilish yoki kasalliklarning oldini olish (83 foiz);
  • immunitet faoliyatini yaxshilash (42 foiz);
  • quvvatni oshirish (31 foiz);
  • inson butunligiga – ong, tana va ruhga ta’sir qilish (27 foiz);
  • xotira yoki diqqatni jamlashni yaxshilash (22 foiz).

AQShda BFQning davlat tomonidan tartibga solinishi

  • AQSh federal qoidalariga ko‘ra, kompaniyalar o‘z BFQlari xavfsiz ekaniga dalillarga ega bo‘lish hamda mahsulot yorliqlari haqqoniy va chalg‘itmaydigan bo‘lishi uchun javobgar. Ishlab chiqaruvchilar BFQni sifatli ishlab chiqarishi, ularda ifloslantiruvchi moddalar va aralashmalar yo‘qligini ta’minlashi va ularni to‘g‘ri yorliqlashi shart.
  • Biroq BFQ ishlab chiqarish va tarqatish qoidalari retseptli va retseptsiz dorilar uchun belgilangan qoidalardan kamroq qat’iy.
  • BFQni tartibga soluvchi AQSh Oziq-ovqat va dori vositalari boshqarmasi (FDA) kompaniyalardan 1994-yilgacha AQShda BFQ tarkibida sotilmagan har qanday yangi tarkibiy qism haqida xavfsizlik ma’lumotlarini taqdim etishni talab qiladi. Boshqa barcha hollarda FDA BFQ bozorga chiqarilishidan oldin ularning xavfsizligi va samaradorligini tekshirish vakolatiga ega emas.

AIVITA izohi: FDA (AQSh) ma’qullagani dori O‘zbekistonda ro‘yxatdan o‘tganini anglatmaydi. Dorilarni shifokor tayinlaydi.

  • FDA qalbakilashtirilgan yoki noto‘g‘ri yorliqlangan BFQga qarshi faqat mahsulot bozorga chiqqanidan keyin chora ko‘rishi mumkin. Taqqoslash uchun: retseptli va retseptsiz dorilar bo‘yicha kompaniyalar dorilar bozorga chiqarilishidan oldin FDAga ularning xavfsizligi va samaradorligi haqida dalillar taqdim etishi kerak.
  • BFQ bozorga chiqqanidan keyin FDA iste’molchilar, qo‘shimcha ishlab chiqaruvchi kompaniyalar va boshqalar xabar qilgan nojo‘ya ta’sirlarni kuzatib boradi. AQShda BFQ xavfsizligi bilan bog‘liq muammolar haqida davlat portali orqali xabar berish mumkin.
  • Agar FDA mahsulotni xavfli deb topsa, ishlab chiqaruvchi yoki distribyutorga qarshi sudga murojaat qilishi, shuningdek, ogohlantirish e’lon qilishi yoki mahsulotni sotuvdan olib tashlashni talab qilishi mumkin. Biroq FDA ma’lumotiga ko‘ra, u BFQ sifatida sotiladigan, tarkibida potensial zararli yashirin moddalar bo‘lishi mumkin bo‘lgan barcha mahsulotlarni tekshira olmaydi. 2023-yilda FDA BFQ tarkibiy qismlarining ochiq onlayn ma’lumotnomasini (Dietary Supplement Ingredient Directory) ishga tushirdi: unda FDA biror tarkibiy qism haqida nima deganini va idora unga nisbatan biror chora ko‘rgan-ko‘rmaganini bilish mumkin.

Sog‘liqqa foydasi hamda organizm tuzilishi va funksiyasiga ta’siri haqidagi da’volar

BFQ yorliqlarida mahsulot biror kasallikni aniqlashi, davolashi, tuzatishi, yengillashtirishi yoki oldini olishi mumkin, deb da’vo qilish mumkin emas: bunday da’volarga faqat dorilar uchun ruxsat beriladi. Biroq BFQ yorliqlarida sog‘liq bilan yoki mahsulotning organizm tuzilishi yoki funksiyasiga ta’siri bilan bog‘liq ayrim turdagi da’volar bo‘lishi mumkin.

  • Sog‘liqqa foydasi haqidagi da’volar qo‘shimcha tarkibidagi modda bilan biror kasallik yoki holat xavfining kamayishi o‘rtasidagi bog‘liqlikni tavsiflaydi. Ular ilmiy dalillarga asoslangan bo‘lishi kerak. Masalan, qo‘shimcha yorlig‘ida «Kalsiy suyak kasalligi – osteoporoz xavfini kamaytirishi mumkin» deb yozilgan bo‘lsa, bu sog‘liqqa foydasi haqidagi da’vo hisoblanadi.
  • Tuzilish va funksiya haqidagi da’volar moddaning organizmning normal tuzilishi yoki funksiyasini saqlashga ta’sirini tavsiflaydi. Masalan, qo‘shimcha yorlig‘ida «Kalsiy suyaklarni mustahkamlaydi» deb yozilgan bo‘lsa, bu tuzilish va funksiya haqidagi da’vo hisoblanadi. BFQ yorliqlaridagi bunday da’volar quyidagi izoh bilan birga berilishi shart: «Bu da’vo Oziq-ovqat va dori vositalari boshqarmasi (FDA) tomonidan baholanmagan. Bu mahsulot biror kasallikni aniqlash, davolash, tuzatish, yengillashtirish yoki oldini olish uchun mo‘ljallanmagan».

Reklama

Reklamani tartibga soluvchi AQSh Federal savdo komissiyasi (FTC) reklama haqqoniy va chalg‘itmaydigan bo‘lishini talab qiladi.

Fan BFQ samaradorligi haqida nima deydi

  • Ba’zi BFQ sog‘liq uchun foydali bo‘lishi mumkin, boshqalarining samaradorligi esa isbotlanmagan.
  • Ayrim qo‘shimchalar bo‘yicha tadqiqotlar ular haqidagi da’volarni tasdiqlamagan. Masalan, bir nechta tadqiqotda exinatseya shamollashni davolashga yordam bermagan, ginkgo biloba esa demensiyada foydasiz bo‘lgan. Ko‘pincha biror BFQ bo‘yicha tadqiqot natijalari bir-biriga zid bo‘ladi – masalan, glyukozamin va xondroitinli qo‘shimchalar osteoartrit belgilarini yengillashtiradimi yoki yo‘qmi, degan masalada.
  • BFQ haqidagi da’volarni tasdiqlovchi kuchli dalillar ko‘pincha yetishmaydi. Masalan, 2022-yilgi sharhda «immunitet tizimini sog‘lom saqlaydi» yoki «tabiiy immunitet kuchaytiruvchi» kabi immunitet bilan bog‘liq da’volarga ega qo‘shimchalarda tez-tez uchraydigan 27 ta tarkibiy qism aniqlangan. Sharh mualliflari har bir tarkibiy qismning samaradorligi bo‘yicha odamlarda o‘tkazilgan puxta tadqiqotlarni ilmiy adabiyotdan izlashgan va bunday dalillarni ulardan faqat sakkiztasi uchun topishgan. Ayrim tadqiqotlar ehtimoliy foyda borligini ko‘rsatgan, lekin dalillar aniq xulosa chiqarish uchun yetarlicha kuchli bo‘lmagan. Immunitet uchun reklama qilinadigan BFQ kasallanishdan himoya qilishga yordam bera oladimi yoki yo‘qmi, buni iste’molchilar bilishi uchun qo‘shimcha tadqiqotlar zarur.

Fan BFQ xavfsizligi va nojo‘ya ta’sirlari haqida nima deydi

  • Yorliqda yozilgan narsa mahsulot tarkibiga mos kelmasligi mumkin. Masalan, FDA BFQ sifatida sotilayotgan mahsulotlarda retseptli dorilarni, jumladan, antikoagulyantlar (masalan, varfarin), tutqanoqqa qarshi dorilar (masalan, fenitoin) va boshqalarni aniqlagan.
  • AQSh davlat idoralari tomonidan 2012-yilda ozish yoki immunitet tizimini qo‘llab-quvvatlash uchun reklama qilinadigan 127 ta BFQ bo‘yicha o‘tkazilgan tadqiqot ularning 20 foizi haqida noqonuniy da’volar qilinganini ko‘rsatgan.
  • Agar sizda biror kasallik yoki xavf omili bo‘lsa yoxud ayrim retseptli yoki retseptsiz dorilarni qabul qilayotgan bo‘lsangiz, ba’zi BFQ sizga zarar yetkazishi mumkin. Masalan, o‘simlik asosidagi qo‘shimcha – dalachoy (Hypericum perforatum) ko‘plab dorilarning samaradorligini pasaytiradi.
  • 2015-yilgi tadqiqotga ko‘ra, AQShda BFQ sababli har yili taxminan 23 000 marta shoshilinch tibbiy yordam bo‘limlariga murojaat qilinadi. Bu bemorlarning ko‘pchiligi – ozish yoki quvvat beruvchi mahsulotlar tufayli yurak muammolariga duch kelgan yoshlar hamda yirik vitamin tabletkalarini qabul qilish tufayli yutish muammolariga duch kelgan keksalar.
  • Garchi bu hali ham kam uchrasa-da, AQShda va boshqa mamlakatlarda BFQ qabul qilayotgan odamlarda jigarning o‘tkir (to‘satdan yuzaga keladigan) shikastlanishi holatlari tobora ko‘proq qayd etilmoqda. Jigar shikastlanishi og‘ir bo‘lishi, shoshilinch jigar transplantatsiyasini talab qilishi va ba’zan o‘lim bilan tugashi mumkin.
  • Ko‘plab BFQ (va ayrim retseptli dorilar) tabiiy manbalardan olinadi, lekin «tabiiy» har doim ham «xavfsiz» degani emas. Masalan, kava (Piper methysticum) o‘simligi qalampirdoshlar oilasiga mansub, lekin kava qo‘shimchalarini qabul qilish jigar kasalligiga olib kelishi mumkin.
  • Ishlab chiqaruvchining «standartlashtirilgan» (yoki «tekshirilgan», «sertifikatlangan») atamasini qo‘llashi mahsulot sifati yoki bir xilligini albatta kafolatlamaydi.

Xavfsizlik choralari

2-rasm. Biologik faol qo'shimchalar qabul qilishda alohida ehtiyotkorlik talab etiladigan guruhlar

2-rasm. Biologik faol qo'shimchalar qabul qilishda alohida ehtiyotkorlik talab etiladigan guruhlar AIVITA sxemasi.

  • Agar sizni operatsiya kutayotgan bo‘lsa, ayrim BFQ qon ketish xavfini oshirishi yoki narkozga (anesteziyaga) bo‘lgan javobga ta’sir qilishi mumkinligini yodda tuting. Operatsiyadan iloji boricha ancha oldin shifokorlaringiz bilan gaplashing va qabul qilayotgan barcha BFQ haqida ularga ayting.
  • Agar homilador bo‘lsangiz, emizayotgan bo‘lsangiz, homilador bo‘lishni rejalashtirayotgan bo‘lsangiz yoki bolaga BFQ berishni o‘ylayotgan bo‘lsangiz, ko‘plab BFQ homilador ayollarda, emizikli onalarda va bolalarda sinovdan o‘tkazilmaganini hisobga oling.
  • Agar BFQ qabul qilayotgan bo‘lsangiz, yorliqdagi ko‘rsatmalarga amal qiling. Nojo‘ya ta’sirlar paydo bo‘lsa, qo‘shimchani qabul qilishni to‘xtating va shifokoringizga murojaat qiling. Qo‘shimcha ishlab chiqaruvchisi bilan bog‘lanish ham foydali bo‘lishi mumkin.

Sog‘lig‘ingizni o‘z nazoratingizga oling: qo‘llayotgan barcha komplementar (qo‘shimcha) tibbiyot usullari haqida shifokorlaringizga ayting. Birgalikda puxta o‘ylangan, to‘liq ma’lumotga asoslangan qarorlar qabul qila olasiz.

Manbalar

Asosiy manbalar

  1. Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4‒17 years in the United States: National Health Interview Survey, 2007‒2012. National health statistics reports; no 78. Hyattsville, MD: National Center for Health Statistics. 2015.
  2. Botanical dietary supplements. Office of Dietary Supplements website. Accessed at ods.od.nih.gov/factsheets/BotanicalBackground-HealthProfessional/ on July 30, 2018.
  3. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National health statistics reports; no 79. Hyattsville, MD: National Center for Health Statistics. 2015.
  4. Cohen PA, Maller G, DeSouza R, et al. Presence of banned drugs in dietary supplements following FDA recalls. JAMA. 2014;312(16):1691-1693.
  5. Crawford C, Brown LL, Costello RB, et al. Select dietary supplement ingredients for preserving and protecting the immune system in healthy individuals: a systematic review. Nutrients. 2022;14(21):4604.
  6. Dietary supplements. Office of Dietary Supplements website. Accessed at ods.od.nih.gov/factsheets/DietarySupplements-HealthProfessional on July 30, 2018.
  7. Dietary supplements. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/DietarySupplements on July 24, 2018.
  8. Dietary supplements: what you need to know. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm on July 30, 2018.
  9. Dietary supplements: what you need to know. Office of Dietary Supplements website. Accessed at ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.aspx on July 30, 2018.
  10. Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. New England Journal of Medicine. 2015;373(16):1531-1540.
  11. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Medica. 2012;78(13):1490-1514.
  12. Hoofnagle JH, Navarro VJ. Drug-induced liver injury: Icelandic lessons. Gastroenterology. 2013;144(7):1335-1336.
  13. Information for consumers on using dietary supplements. U.S. Food and Drug Administration website. Accessed at www.fda.gov/food/dietarysupplements/usingdietarysupplements on July 30, 2018.
  14. Kantor ED, Rehm CD, Du M, et al. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316(14):1464-1474.
  15. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399-1408.
  16. Questions and answers on dietary supplements. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm480069.htm on July 30, 2018.
  17. Stussman BJ, Black LI, Barnes PM, Clarke TC, Nahin RL. Wellness-related use of common complementary health approaches among adults: United States, 2012. National health statistics reports; no 85. Hyattsville, MD: National Center for Health Statistics. 2015.

Boshqa manbalar

  1. Advertising FAQ’s: a guide for small business. Federal Trade Commission website. Accessed at www.ftc.gov/tips-advice/business-center/guidance/advertising-faqs-guide-small-business on July 30, 2018.
  2. Ashley JT, Ward JS, Anderson CS, et al. Children’s daily exposure to polychlorinated biphenyls from dietary supplements containing fish oils. Food Additives & Contaminants: Part A. 2013;30(3):506-514.
  3. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419-1425.
  4. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. The American Journal of Cardiology. 2012;110(4):526-529.
  5. Brinkley TE, Lovato JF, Arnold AM, et al. Effect of ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. American Journal of Hypertension. 2010;23(5):528-533.
  6. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795-808.
  7. Cortés-Jofré M, Rueda JR, Corsini-Muñoz G, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews. 2012;(10):CD002141. Accessed at http://www.cochranelibrary.com on July 25, 2018.
  8. Crawford C, Brown LL, Costello RB, et al. Immune supplements under the magnifying glass: an expert panel develops priorities and evidence-based recommendations for future research regarding dietary supplements. Journal of Integrative and Complementary Medicine. March 1, 2023. [Epub ahead of print].
  9. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262.
  10. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, et al. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database of Systematic Reviews. 2015;(12):CD007950. Accessed at https://www.cochranelibrary.com on July 25, 2018.
  11. Dietary supplement products & ingredients. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/DietarySupplements/ProductsIngredients/default.htm on July 30, 2018.
  12. Feucht C, Patel DR. Herbal medicines in pediatric neuropsychiatry. Pediatric Clinics of North America. 2011;58(1):33-54.
  13. Fortman SP, Burda BU, Senger CA, et al. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2013;159(12):824-834.
  14. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases. 2015;74(5):851-858.
  15. Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology. 2012;69(7);836-841.
  16. Gordon RY, Cooperman T, Obermeyer W, et al. Marked variability of monacolin levels in commercial red yeast rice products. Archives of Internal Medicine. 2010;170(19):1722-1727.
  17. Guidance for industry: questions and answers regarding adverse event reporting and recordkeeping for dietary supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm171383.htm on July 30, 2018.
  18. Grodstein F, O’Brien J, Kang JH, et al. A randomized trial of long-term multivitamin supplementation and cognitive function in men: The Physicians’ Health Study II. Annals of Internal Medicine. 2013;159(12):806-814.
  19. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews. 2013;(1):CD000980. Accessed at http://www.cochranelibrary.com on July 30, 2018.
  20. Herrero-Beaumont G, Ivorra JA, del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis & Rheumatism. 2007;56(2):555-567.
  21. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. 2002;(2):CD001520. Accessed at https://www.cochranelibrary.com on July 27, 2018.
  22. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases. 2016;75(1):37-44.
  23. Is it really “FDA approved?” U.S. Food and Drug Administration website. Accessed at www.fda.gov/ForConsumers/ConsumerUpdates/ucm047470.htm on July 30, 2018.
  24. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. 2009;60(2):524-533.
  25. Karsch-Völk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. Cochrane Database of Systematic Reviews. 2014;(2):CD000530. Accessed at http://www.cochranelibrary.com on July 25, 2018.
  26. Kenfield SA, Van Blarigan EL, DuPre N, et al. Selenium supplementation and prostate cancer mortality. Journal of the National Cancer Institute. 2014;107(1);360.
  27. Label claims for conventional foods and dietary supplements. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/LabelingNutrition/ucm111447.htm on July 30, 2018.
  28. Kim J, Choi J, Kwon SY, et al. Association of multivitamin and mineral supplementation and risk of cardiovascular disease: a systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes. 2018;11(7);e004224.
  29. Liira J, Verbeek JH, Costa G, et al. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database of Systematic Reviews. 2014;(8):CD009776. Accessed at http://www.cochranelibrary.com on July 30, 2018.
  30. Liu ZL, Xie LZ, Zhu J, et al. Herbal medicines for fatty liver diseases. Cochrane Database of Systematic Reviews. 2013;(8):CD009059. Accessed at https://www.cochranelibrary.com on July 25, 2018.
  31. Macpherson H, Pipingas A, Pase MP. Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition. 2013;97(2):437-444.
  32. Masada-Atsumi S, Kumeta Y, Takahashi Y, et al. Evaluation of the botanical origin of black cohosh products by genetic and chemical analyses. Biological and Pharmaceutical Bulletin. 2014;37(3):454-460.
  33. Moyer VA. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2014;160(8):558-564.
  34. Navarro VJ, Seeff LB. Liver injury induced by herbal complementary and alternative medicine. Clinics in Liver Disease. 2013;17(4):715-735.
  35. New dietary ingredients in dietary supplements—background for industry. U.S. Food and Drug Administration website. Accessed at www.fda.gov/Food/DietarySupplements/ucm109764.htm on July 30, 2018.
  36. NIH centers for advancing research on botanical and other natural products (CARBON) program. Office of Dietary Supplements website. Accessed at ods.od.nih.gov/Research/Dietary_Supplement_Research_Centers.aspx on July 30, 2018.
  37. Office of Inspector General. Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements. Office of Inspector General website. Accessed at https://oig.hhs.gov/oei/reports/oei-01-11-00210.asp on July 25, 2018.
  38. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Archives of Internal Medicine. 2002;162(18):2113-2123.
  39. Pawar RS, Grundel E, Fardin-Kia AR, et al. Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC-MS/MS methods. Journal of Pharmaceutical and Biomedical Analysis. 2014;88:457-466.
  40. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256.
  41. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Annals of the Rheumatic Diseases. 2010;69(8):1459-1464.
  42. Seeff LB, Bonkovsky HL, Navarro VJ, et al. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology. 2015;148(3):517-532.
  43. Singh JA, Noorbaloochi S, MacDonald R, et al. Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews. 2015;(1):CD005614. Accessed at https://www.cochranelibrary.com on July 25, 2018.
  44. Snitz BE, O’Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009;302(24);2663-2670.
  45. Song Y, Xu Q, Park Y, et al. Multivitamins, individual vitamin and mineral supplements, and risk of diabetes among older U.S. adults. Diabetes Care. 2011;34(1):108-114.
  46. Tainted products marketed as dietary supplements_CDER. U.S. Food and Drug Administration. Accessed at www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=tainted_supplements_cder&displayAll=false&page=6 on July 30, 2018.
  47. Wallace ED, Oberlies NH, Cech NB, et al. Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics. Food and Chemical Toxicology. 2018;120:439-447.

Bob manbasi: U.S. National Institutes of Health — «Using Dietary Supplements Wisely». Источник: National Center for Complementary and Integrative Health (NCCIH), «Using Dietary Supplements Wisely» — https://www.nccih.nih.gov/health/using-dietary-supplements-wisely. Общественное достояние (работа правительства США). Перевод выполнен AIVITA; NCCIH, NIH и правительство США не одобряли этот перевод и не несут за него ответственности. / Manba: NCCIH, «Using Dietary Supplements Wisely». Tarjima AIVITA tomonidan qilingan; NCCIH, NIH va AQSh hukumati bu tarjimani ma’qullamagan.

Mualliflar: National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA)

Litsenziya: Jamoat mulki

Asos: Работа федерального правительства США (17 U.S.C. §105), общественное достояние. Использован только текст; изображения, логотипы и символика оригинала не используются. / AQSh federal hukumatining asari (17 U.S.C. §105), jamoat mulki. Faqat matn ishlatilgan; asl nusxadagi rasmlar, logotiplar va ramzlar ishlatilmagan.

Материалы U.S. National Institutes of Health — общественное достояние (U.S. public domain); источник каждой главы указан в её конце. Перевод и адаптация — AIVITA.